Keeping the Medical in Medical Marijuana: An Evidence-Based Review

Friday, September 23, 2016

Program Agenda

Registration: 10:00-10:30 a.m.

Lecture: 10:30-11:30 a.m.

Continuing Education Verification Evaluation, Adjournment:  11:30 a.m.

Program Faculty


Edward M. Bednarczyk, PharmD, FCCP, FAPhA
Clinical Associate Professor, Chairman
Department of Pharmacy Practice
UB School of Pharmacy and Pharmaceutical Sciences

Program Overview

Most patients and some clinicians are unaware of the existence of FDA approved cannabinoids and of common or serious adverse effects of medical marijuana. There is frequent confusion of the pharmacology of cannabinoids vs. medical marijuana. Learn how existing legislation in New York State for medical marijuana impacts the practice environment.

Learning Objectives

  • Differentiate between medical marijuana and FDA approved cannabinoids
  • List the adverse effects of medical marijuana
  • List conditions that may be responsive to cannabinoid therapy
  • Compare the legislation in NYS that addresses medical marijuana in the existing FDA Process

Continuing Education Information


The University at Buffalo School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based activity has been assigned ACPE# 0044-0000-16-040-L01-P and will award 1 contact hours (0.1 CEU.) of continuing pharmacy education credit.  Credit will be uploaded to the CPE Monitor for those who attend the full session and complete a CE attendance document. No partial credit will be awarded.